Release Date: May 16, 2017
Expiration Date: May 31, 2019 (subject to change)
- CE for this activity will not be available after this date.
A post impact survey invitation will be sent to all learners who complete this activity (see below). Participation is completely optional.
Elevated LDL-C levels remain an unresolved problem among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia. Reasons for this may include widespread statin intolerance leading to low patient adherence to statin treatment. Newly approved PCSK9 inhibitors offer a promising approach to the secondary prevention of ASCVD by lowering LDL-C in combination with statins. As the science and therapeutic management of hypercholesterolemia continue to advance, continuing education for health care professionals will become increasingly important in order to improve outcomes in patients with hypercholesterolemia and ASCVD. This activity will examine the current discussions surrounding statin use and the potential application of PCSK9 inhibitors. This activity will educate NPs and give them the tools needed to make objective and evidence-based treatment decisions for their patients with ASCVD and hypercholesterolemia.
This is a recorded version of live presentations offered through the AANP CE Series. If you received credit for this activity by attending a live session, you may not receive duplicate credit for the same content in a different format. A Post Impact Survey (optional) will be available 30-90 days after completion of this activity (see Post Impact Survey, below).
This group lecture program has been designed for nurse practitioners involved in the care of patients with hypercholesterolemia.
Upon completion of this activity, the participant should be able to:
- Outline the mechanisms of action for PCSK9 inhibitors.
- Identify potential advantages, disadvantages, and clinical uses for PCSK9 inhibitors.
- Discuss guideline controversies with regard to statin use for the treatment of patients with ASCVD and hypercholesterolemia.
- Develop a plan to increase patient adherence to treatment regimens for hypercholesterolemia.
Joyce L. Ross, MSN, CRNP, CLS, FNLA, FPCNA
Lynne T. Braun, PhD, CNP, FAHA, FAANP, FPCNA, FAAN
This activity was developed in accordance with AANP Accreditation Standards and Policies in cooperation with MCM Education, Newtown, PA. It is supported by educational funding provided by Amgen and Sanofi US and Regeneron Pharmaceuticals.
Ms. Ross discloses that she has served on the advisory board for Akcea Therapeutics and Amarin Corporation, and on the speakers bureau for Amarin Corporation, AstraZeneca, AbbVie, Amgen, Sanofi/Regeneron, and Kowa Pharmaceuticals America, Inc.
Dr. Braun discloses that she has served as an author and on the advisory board for UpToDate/WoltersKluwer.
The handout provided is designed to complement the presentation titled Secondary Prevention of ASCVD: Novel Therapies to Improve Outcomes in Patients with Hypercholesterolemia. None of the content may be reproduced in any form without prior written permission from the publisher. This educational activity may contain opinions of the speaker from their personal experience.
The content of the printed slides was accurate as of the publication date.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. It may contain opinions of the speakers from their personal experience.
CE Credit Instructions
- Complete the educational content completely: Watch the entire video presentation.
- Review all additional materials provided (handouts, posttest reviews, other downloadable resources).
- After completing all content, go to Steps To Receive Credit for this activity. Complete the posttest and evaluation for full AANP CE/Rx credit.
Post Impact Survey:
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to participate in a Post Impact Outcomes Survey (PI Survey). Participation in the survey is optional and does not affect the credit earned. The PI surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.
©2017. The American Association of Nurse Practitioners. All rights reserved